



Australian Government  
Canberra

1<sup>st</sup> June 2015

Dear Madam/Sir,

### **R&D Tax incentive**

The R&D Tax incentive is an essential component of investment in innovation.

Proteomics International is a newly ASX-listed life science company (code: PIQ) focused on the area of proteomics – the industrial scale study of the structure and function of proteins. Founded in 2001, the Company has grown organically to become a global leader in its field, servicing blue-chip clients around the planet. It received the world's first ISO 17025 laboratory accreditation for proteomics services, and operates from purpose built, state-of-the art facilities at the Harry Perkins Institute of Medical Research in Perth, Western Australia.

Proteomics International has a proven business model which uses its proprietary technology platform to operate across three synergistic proteomics-based business units in analytical services, diagnostics and drug discovery. The company has self-funded \$7m of R&D and is now in an expansion phase, to grow its pipelines, strengthen deal flow and commercialise its products and intellectual property.

A substantial proportion of the Company's investment in R&D is as a direct consequence of the R&D Tax incentive. There are no alternative schemes that would match the current R&D Tax incentive for efficiency and return on investment. It must be kept as is. If the R&D Tax incentive is closed down or the cash component removed, then our company, along with many others, will move its R&D operations offshore.

The R&D Tax incentive must be enriched and broadened. Dismantle it at your peril.

Yours sincerely,

Dr. Richard J Lipscombe  
Managing Director